Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROQR THERAPEUTICS N.V.

(PRQR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2022 01/14/2022 01/18/2022 01/19/2022 01/20/2022 Date
6.75(c) 6.76(c) 6.38(c) 6.25(c) 5.52(c) Last
189 100 247 556 242 406 650 790 1 351 159 Volume
-3.02% +0.15% -5.62% -2.04% -11.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 6,21 M - -
Net income 2021 -67,6 M - -
Net cash position 2021 140 M - -
P/E ratio 2021 -5,17x
Yield 2021 -
Sales 2022 4,30 M - -
Net income 2022 -78,2 M - -
Net cash position 2022 63,0 M - -
P/E ratio 2022 -5,01x
Yield 2022 -
Capitalization 393 M 393 M -
EV / Sales 2021 40,6x
EV / Sales 2022 76,7x
Nbr of Employees -
Free-Float 92,3%
More Financials
Company
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic... 
More about the company
Ratings of ProQR Therapeutics N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROQR THERAPEUTICS N.V.
01/04PROQR THERAPEUTICS N : Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Il..
PU
01/04ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial..
AQ
01/04ProQR Therapeutics N.V. Announces Last Patient Has Completed 12 Month Visit in Phase 2/..
CI
2021PROQR THERAPEUTICS N : Announces Amendment to Convertible Debt Financing Agreement with Po..
PU
2021ProQR Therapeutics Gains Access to Additional $90 Million in Convertible Debt Financing
MT
2021ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Venture..
AQ
2021PROQR THERAPEUTICS N : AGM 2021 Minutes
PU
2021PROQR THERAPEUTICS N.V.(NASDAQGM : PRQR) added to NASDAQ Biotechnology Index
CI
2021ProQR Therapeutics Commences Dosing in Phase 2/3 Pivotal Trials of QR-421a in Retinitis..
MT
2021PROQR THERAPEUTICS N : Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-42..
PU
2021ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A M..
GL
2021ProQR Therapeutics N.V. Announces First Patients Dosed in Phase 2/3 Pivotal Trials of Q..
CI
2021PROQR THERAPEUTICS N : Announces Highlights from Analyst Event - Form 6-K
PU
2021ProQR Announces Highlights from Analyst Event
GL
2021PROQR THERAPEUTICS N : Analyst Event 2021
PU
More news
News in other languages on PROQR THERAPEUTICS N.V.
01/04ProQR Therapeutics N.V. annonce que le dernier patient a terminé la visite de 12 mois d..
01/04SENSORION : une nomination au conseil d'administration
2021Les actions du secteur de la santé terminent près de leur plus bas niveau intrajournali..
2021Les actions du secteur de la santé aggravent leurs pertes antérieures
2021ProQR Therapeutics dévoile sa collaboration avec Lilly dans le domaine de la recherche ..
More news
Analyst Recommendations on PROQR THERAPEUTICS N.V.
More recommendations
Chart PROQR THERAPEUTICS N.V.
Duration : Period :
ProQR Therapeutics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROQR THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,52 $
Average target price 24,86 $
Spread / Average Target 350%
EPS Revisions
Managers and Directors
Daniel Anton de Boer Chief Executive Officer
Smital Shah Chief Financial & Business Officer
Domenico Valerio Chairman-Supervisory Board
Aniz Girach Chief Medical Officer
Jennifer Pluim Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
PROQR THERAPEUTICS N.V.-31.09%393
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805